NEW YORK (AP) — Biogen Idec Inc. and Genentech said Friday that the Food and Drug Administration has approved an additional use for blockbuster cancer drug Rituxan as a first-line maintenance treatment for patients with follicular lymphoma, a cancer of the blood.
Biogen and Genentech, which is part of Swiss pharmaceutical firm Roche Group, said the disease is considered incurable and is characterized by
No comments:
Post a Comment